DENVER — MCO-010, an optogenetic therapy, demonstrated vision improvements for patients with retinitis pigmentosa at 3 years, according to a presenter at the Association for Research in Vision and Ophthalmology meeting.
Optogenetic treatment for retinal disease focuses on restoring light sensitivity to retinal cells through the delivery of synthetic protein, Vinit B. Mahajan, MD, PhD, a retina specialist at Stanford University, told Healio. MCO-010 (Nanoscope Therapeutics), he said, is gene-agnostic.
{{VIDEO}}
“We're not picking a specific [form of] retinitis pigmentosa (RP),” Mahajan told